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Abstract
Purpose of Review In acute ST-segment elevation myocardial infarction (STEMI), successful restoration of blood flow in the
infarct-related coronary artery may not secure effective myocardial reperfusion. The mortality and morbidity associated with
acute MI remain significant. Microvascular obstruction (MVO) represents failed microvascular reperfusion. MVO is under-
recognized, independently associated with adverse cardiac prognosis and represents an unmet therapeutic need.
Recent Findings Multiple factors including clinical presentation, patient characteristics, biochemical markers, and imaging
parameters are associated with MVO after MI.
Summary Impaired microvascular reperfusion is common following percutaneous coronary intervention (PCI). New knowledge
about disease mechanisms underpins precision medicine with individualized risk assessment, investigation, and stratified ther-
apy. To date, there are no evidence-based therapies to prevent or treat MVO post-MI. Identifying novel therapy for MVO is the
next frontier.
Keywords Microvascular obstruction .Myocardial infarction .MRI . Stratifiedmedicine
Introduction
Acute ST-segment elevation myocardial infarction (STEMI)
is a major cause of premature death and morbidity [1].
Restoration of epicardial coronary blood flow by PCI is the
evidence-based standard of care [2, 3]. Significant progress
has been made in terms of reducing time to revascularization
over the last two decades [4]. Despite this, figures for short-
termmortality remain unchanged and the incidence of chronic
heart failure post-MI is high [2, 5].
Microvascular reperfusion is the ability to perfuse the cor-
onary microcirculation in a previously ischemic region after
opening the epicardial vessel. Successful restoration of epicar-
dial blood flow does not guarantee myocardial reperfusion.
There is evidence of impaired microvascular perfusion on
cardiac magnetic resonance (CMR) imaging in over half of
patients following STEMI despite angiographic patency of the
infarct-related artery post-PCI [6]. This acute and potentially
reversible complication is known as microvascular obstruc-
tion (MVO) and is thought to occur post-coronary reperfusion
as a result of endothelial disruption and microvascular thrombi
[7]. In the absence of adequate reperfusion, progression to
irreversible myocardial hemorrhage can occur at the infarct
core [8]. MVO and subsequent intramyocardial hemorrhage
(IMH) are strongly associated with mortality and hospitaliza-
tion for heart failure [9•].
In clinical practice, MVO is likely to pass undetected in
many cases. The limits of contemporary coronary revascular-
ization in known myocardial ischemia have been highlighted
in the recent ISCHEMIA trial [10]. The focus of reperfusion
therapy in STEMI is extending to consider the preservation of
distal coronary microvasculature, in turn contemporary prac-
tice guidelines call for research to identify new treatments for
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MVO [2]. An understanding of the predictors of microvascu-
lar reperfusion after MI is central to the development of inves-
tigative pathways and trial design and lays the foundations for
much needed targeted therapeutic intervention and stratified
medicine in this cohort.
In this review, we consider the definition of microvascular
reperfusion after MI on a practical basis in a range of clinical
settings throughout the patient journey. We provide an over-
view of the predictors of coronary microvascular dysfunction
in this context and address the concept of stratified medicine
in the future.
Defining Microvascular Reperfusion After
Myocardial Infarction—a Practical Approach
Pathophysiology and Natural History
Coronary microvasculature holds 20% of myocardial blood
volume and modulates myocardial perfusion [11, 12].
Impaired microvascular reperfusion is a complex pathophys-
iological process that stems from initial embolic phenomena
and the resultant ischemic sequelae of edema, hemorrhage,
and intracellular substance release. This results in luminal ob-
struction, external compression, and endothelial dysfunction
with impaired vasomotion [13–15]. In the event of inadequate
reperfusion, chronic hibernation and cell death occur leading
to the development of ischemic cardiomyopathy and clinical
heart failure [16].
The evolution of microvascular reperfusion after MI is rel-
evant when considering assessment methods used to define it.
Experimental models indicate that myocardial perfusion de-
fects occur during the process of reperfusion [17].
Radiological evidence of MVO in humans is maximal at an
early stage (4–12 h post-reperfusion), remains stable to day
two and then decreases [6]. By 1-month post-reperfusion,
MVO has reversed in 50% of patients, and in the majority of
cases, there is complete resolution after 8 months [18, 19].
IMH is a manifestation of severe microvascular injury that
only occurs in the context of MVO and exhibits a progressive
time course to a peak at 2 days [20].
Coronary microvascular dysfunction runs a dynamic tem-
poral course following reperfusion in acute MI. The definition
of microvascular reperfusion is dependent on method of de-
tection and also the time point at which assessment takes
place. Impaired microvascular reperfusion defined using dif-
ferent methods is prognostically important [9•, 21•, 22].
MVO occurs following reperfusion in both STEMI and
non-ST-elevation acute myocardial infarction (NSTEMI).
NSTEMI is a heterogeneous condition with a variable clinical
course that typically exhibits a relapsing and remitting myo-
cardial ischemia that is less clamant than is the case for
STEMI. Rates of MVO following early revascularization in
NSTEMI are lower [23, 24] but nonetheless associated with
adverse prognosis [25]. Similar mechanisms underpin MVO
in both conditions and there may be shared predictive factors.
The majority of research evaluating the prevalence and prog-
nostic impact of MVO has been undertaken in STEMI popu-
lations, and this provides a more reliable basis for the defini-
tion and prediction of microvascular reperfusion after MI.
Clinical Setting
The test options for assessing reperfusion injury differ accord-





The thrombolysis in myocardial infarction (TIMI) flow grad-
ing system is a widely used visual assessment of flow appear-
ance that provides an immediate evaluation of microvascular
reperfusion [26]. Complete antegrade flow following inter-
vention is denoted as “TIMI 3” and is associated with im-
proved survival compared to reduced flow grades [27].
There is evidence of impaired microcirculation in the majority
of patients with significantly reduced TIMI grade [9•]; there-
fore, the angiographic definition of MVO is TIMI grade < 2.
TIMI grade does not correlate well with MVO defined by
“gold standard” CMR imaging [28, 29]. Multiple studies have
reported MVO in more than half of those with optimal TIMI
grade 3 flow following PCI [6, 28, 30].
Methods such as myocardial blush grading (MBG) and
fluoroscopy assisted scoring have been introduced to enhance
visual assessment and reduce operator variability [31, 32].
MBG grade 3 indicates successful microvascular reperfusion,
whereas grades 0–1 define MVO in this setting. While these
techniques are intended to improve classification, correlation
with MVO is only moderate, and these techniques are not
relied upon in clinical practice [33–35].
The spatial resolution of coronary angiography is approx-
imately tenfold larger than the diameter of arterioles that gov-
ern myocardial blood flow [36]. Visual angiographic assess-
ment remains an inaccurate means to define microvascular
reperfusion following STEMI and has a limited role.
Intracoronary Electrocardiogram (IC-ECG)
An intracoronary unipolar electrocardiogram can be acquired
while in the catheterization laboratory by connecting the prox-
imal end of the angioplasty guidewire to a monitor using a
crocodile clip [37]. IC-ECG is more sensitive than conven-
tional 12-lead ECG at detecting regional myocardial ischemia
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and has the added benefit of real-time information with no
precordial leads that can obscure angiographic images [38].
Resolution of ST-elevation (STR) defines successful micro-
vascular reperfusion in this context and correlates with im-
proved survival after STEMI [39, 40]. STR demonstrates pre-
dictive value for MVO at 4 days post-STEMI but lacks spec-
ificity [41].
Invasive Coronary Physiology
Coronary physiology measurements using diagnostic
guidewire sensors have emerged as useful tools in the diagno-
sis and management of disorders of coronary function [36].
These metrics provide an immediate assessment of microvas-
cular resistance and can be used to define microvascular re-
perfusion post-PCI. There are a number of parameters that are
relevant in this context (Table 1).
Index of Microcirculatory Resistance (IMR) IMR represents the
minimum microvascular resistance during adenosine-induced
hyperemia and is a validated measure of microcirculatory re-
perfusion [21•, 42]. Low IMR values indicate successful mi-
crovascular reperfusion, whereas raised values (≥ 25) suggest
MVO and are associated with increased rates of heart failure
hospitalization and major adverse cardiovascular events
(MACE) [21•, 30, 43, 44]. Current evidence suggests that
IMR is the metric with the highest predictive accuracy for
MVO and IMH. In the BHF MR-MI study, an IMR of > 27
had the highest diagnostic accuracy for MVO (0.65) and myo-
cardial hemorrhage (0.68) revealed by CMR 2 days post-MI
[30]. Furthermore, a higher IMR (e.g., > 40) corresponds less
with CMR findings and more with all-cause death and heart
failure [21•, 45]. These findings imply a gradient of prognostic
significance: an IMR ≥ 25 is the upper limit of the reference
range, an IMR of 28 corresponds with microvascular pathol-
ogy that may be reversible, i.e., microvascular obstruction,
and an IMR of 40 or higher is most closely associated with
adverse cardiovascular events. This is our interpretation of the
clinical significance of the different IMR thresholds which
hopefully clarifies the utility of this tool when considering
its role in clinical practice [46].
Hyperemic Microvascular Resistance (HMR) HMR is calculat-
ed by dividing distal coronary pressure by mean Doppler flow
velocity at peak hyperemia. In keeping with IMR, low values
indicate successful microvascular reperfusion whereas raised
values (≥ 2.5) are suggestive of MVO [47]. Predictive accura-
cy is comparable to IMR although there is less empirical ev-
idence and real-world applicationmay be limited by technique
complexity.
Coronary Flow Reserve (CFR) CFR reflects epicardial and mi-
crocirculatory vasodilator capacity and can be derived utiliz-
ing Doppler or thermodilution techniques [48]. High CFR
readings indicate successful microcirculatory reperfusion and
low values (≤ 2) correlate with MVO, although this is not a
consistent trend in the literature [30]. CFR is a broad measure
and lacks the predictive accuracy and reproducibility to quan-
tify microvascular reperfusion after MI.
Resistive Reserve Ratio (RRR) RRR is a measure of the differ-
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Fig. 1 Markers of impaired microvascular reperfusion after STEMI—investigation hierarchy during the patient journey
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resistance at maximal hyperemia and reflects the ability of the
coronary microcirculation to vary resistance to hyperemic
stimuli. Elevated values indicate increased vasodilator capac-
ity and thus successful microvascular reperfusion. Reduced
RRR (≤ 1.7) is associated with the presence and extent of
MVO, albeit to a lesser extent than IMR when using dichoto-
mized values [21•, 49, 50].
Temperature Recovery Time (TRT) TRT is the time taken for
the temperature at the guidewire tip to return to baseline dur-
ing maximal hyperemia. Low TRT indicates successful mi-
crocirculatory reperfusion. Recent research demonstrates cor-
relation between MVO and longer recovery time (TRT ≥ 0.5)
with similar predictive accuracy to IMR [51].
Coronary Pressure-Flow Velocity LoopsDuringmid-diastole, a
linear relationship exists between pressure and flow. Coronary
zero flow pressure (PZF) is an index derived from the extrap-
olation of coronary pressure-flow velocity loops [52].
Theoretically this represents the intraluminal pressure re-
quired to maintain vessel patency in the absence of coronary
flow, i.e., against extra-vascular compressive forces only.
Low PZF indicates successful microcirculatory reperfusion,
and raised values are predictive of CMR-defined MVO fol-
lowing STEMI (AUC 0.75, 95% CI 0.55–0.89; p = 0.01) [47].




Echocardiography is a standard care assessment in pa-
tients following an acute MI. Reduced ejection fraction
carries prognostic significance and is more common in
populations with MVO [6, 55]. Regional wall motion ab-
normality is a surrogate for infarct size, which correlates
positively with MVO [9•]. Although readily available and
useful for risk stratification, standard echocardiography
lacks the specificity to define successful microvascular
reperfusion after MI.
The coronary flow-velocity ratio (CFVR) is derived from
diastolic flow measurements in epicardial coronary arteries
during rest/stress using Doppler echocardiography. In the ab-
sence of epicardial flow limitation, CFVR > 2.5 indicates nor-
mal microvascular function [11, 56]. To our knowledge, this
technique has not been validated against CMR-defined MVO
inmajor studies. Speckle-tracking techniques for strain assess-
ment in 2D and 3D models demonstrate significant associa-
tion with CMR-defined MVO in small studies [57, 58].
Myocardial contrast echo (MCE) uses ultrasound to visualize
micro-bubble contrast in the myocardium following intrave-
nous injection. Contrast signal intensity is a surrogate for
myocardial blood flow and successful microvascular reperfu-
sion is indicated by rapid and uniform myocardial contrast
enhancement. Contrast delay or the absence of myocardial
contrast opacification suggests MVO [59, 60]. This approach
has demonstrated utility in the identification of MVO as a
negative prognostic marker [22, 61]. When compared to
CMR in a canine model, both techniques correlate well with
MVO histologically, although CMR was found to have in-
creased sensitivity in reduced blood flow states [62]. Clinical
use ofMCE is limited by operator dependence, cost, advanced
skill requirement, and limited spatial resolution.
Cardiac Magnetic Resonance Imaging (CMR)
Regional myocardial ischemia results in edema (increased
water content) and prolongs longitudinal (T1) and









IMR Minimum microvascular resistance at peak hyperemia Elevated (≥25) – Highest predictive
accuracy for MVO
HMR Distal coronary pressure divided by mean Doppler flow
velocity
Elevated (≥2.5) Similar Complex technique
TRT Time for temperature at the guidewire tip to return to
baseline during maximal hyperemia
Elevated (≥0.5) Similar Limited use in clinical
practice
CFR Epicardial and microcirculatory vasodilator capacity derived
from Doppler or thermodilution
Reduced (≤2) Reduced Broad measure with low
predictive accuracy
RRR Difference between basal resting tone in the
microcirculation and resistance at maximal hyperemia
Reduced (≤1.7) Reduced –
PZF Index derived from an extrapolation of coronary
pressure-flow velocity loops
Elevated Unclear –
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transverse (T2) relaxation times increasing regional signal
intensity on CMR images [63]. MVO is defined as a lack
of gadolinium enhancement (hypointense core) within
hyper-enhanced infarct areas [62].
Contrast-enhanced CMR is considered the gold-
standard in vivo assessment of MVO and is the reference
diagnostic test in trials that have uncovered the prognostic
implications of impaired microvascular reperfusion fol-
lowing MI [9•, 64]. CMR has been validated histological-
ly in this context and its value is increasingly recognized
in terms of characterizing infarct pathology as well as
providing accurate structural and functional myocardial
assessment [8, 65].
Other Imaging Modalities
Delayed contrast-enhanced CT has potential for tissue charac-
terization; however, unlike CMR, CT is limited by image
quality and radiation exposure [66].
Nuclear imaging is frequently used to assess myocar-
dial blood flow, and positron emission tomography (PET)
is a validated means of coronary vasomotor function test-
ing. Myocardial scintigraphy can detect capillary reperfu-
sion defects following coronary thrombolysis [67]. The
role of these techniques in defining microvascular reper-
fusion following MI is less clear and accessibility out-
with main centers is limited.
Clinical Risk Factors for Failed Microvascular
Reperfusion After Myocardial Infarction
Well-recognize factors linked to adverse cardiac progno-
sis may confer their detrimental effects via microvascular
obstruction. Underlying health conditions, clinical presen-
tation features, ECG parameters, and laboratory results
have a role in predicting the likelihood of successful mi-
crovascular reperfusion after MI (Fig. 2). Microvascular
obstruction on CMR is the gold-standard assessment of
impaired microvascular reperfusion and represents the
benchmark comparison when reviewing predictive factors
unless otherwise stated.
Cardiovascular Risk Factors
Cardiovascular risk factors are common in patients pre-
senting with STEMI. Comorbid conditions, such as hy-
pertension and diabetes, are associated with endothelial
dysfunction [68] and could signify underlying microvas-
cular disease that influences the extent of microvascular
reperfusion following MI.
Diabetes, Hyperglycemia, and Obesity
Diabetes has established multisystemic macro- and microvas-
cular complications. The condition increases the probability of
a cardiovascular event and worsens prognosis thereafter [69].
Hyperglycemia exerts a detrimental effect on endothelial cell
function and impairs arterial vasodilation [70]. In the setting of
acute MI, poor glycemic control is associated with worse car-
diac outcomes [71].
Large studies have been unable to demonstrate con-
vincing association between pre-existing diabetes and
MVO following re-perfused STEMI. There does howev-
er appears to be a link between hyperglycemia at pre-
sentation and subsequent microvascular dysfunction fol-
lowing PCI [72, 73]. In 93 patients who underwent
CMR at 7 days following reperfusion, admission glu-
cose level was an independent predictor of MVO (OR
1.014, 95% CI 1.004–1.023; p = 0.006) [74]. This rela-
tionship exists even in non-diabetic populations [75]. To
date, MVO has proven resistant to therapeutic modifica-
tion [76, 77].
Obesity (defined by raised body mass index) has not been
shown to demonstrate significant correlation with microvas-
cular perfusion defects post-STEMI [30, 78].
Hypertension
Hypertension is associated with endothelial dysfunction
and is a strong negative prognostic indicator after
STEMI [79–81]. However, studies utilizing both CMR
and invasive coronary physiology have been unable to
demonstrate significant association between pre-existing
hypertension and microvascular dysfunction following
acute MI [79, 82].
Hypercholesterolemia
Hypercholesterolemia is associated with coronary heart dis-
ease and cholesterol-lowering therapy conveys mortality ben-
efit in this cohort [83]. A degree of controversy exists sur-
rounding the value of admission cholesterol levels and clinical
outcomes following STEMI [84, 85]. Animal models using
histological diagnosis demonstrate increasedMVO in the con-
text of coronary reperfusion after a cholesterol-enriched diet
[86]. Associations between hypercholesterolemia and MVO
following re-perfused MI in humans are less clear. Reindl
et al. reported admission low-density lipoprotein (LDL) levels
to be an independent predictor of MVO in over 200
revascularized STEMI patients (OR 1.02, 95% CI 1.01–
1.02; p = 0.002) [87]. Other clinical trials using CMR- and
MCE-based diagnostic assessments did not report significant
differences in patients with normal versus raised cholesterol
levels [30, 88].
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Smoking
Cigarette smoking negatively impacts coronary endothelial
function and increases the risk of developing cardiovascular
disease [89, 90]. There is limited evidence to suggest that
smoking is associated with MVO post-STEMI and links be-
tween smoking and IMH are yet to be clearly defined [30,
91–93]. Haig et al. report evidence of improvedmicrovascular
perfusion defined by coronary physiology and ECG parame-
ters in the acute phase after reperfusion in smokers, followed
by subsequent development of microvascular injury.
Ultimately, when adjusted for infarct size, cigarette smoking
was identified as an independent predictor for IMH (OR 2.76,
95% CI 1.42–3.77; p = 0.003) but not MVO [94].
Non-modifiable Patient Characteristics
Age
Elderly STEMI patients who have undergone revasculariza-
tion are more likely to demonstrate impaired microvascular
reperfusion defined by ECG STR and angiographic TIMI
grade [93, 95–97]. Large contemporary studies examining
microvascular reperfusion following STEMI using the more
robust measure of CMR-definedMVO have not demonstrated
clear association with age [9•, 30]. A small trial examining
predictive factors in 97 patients following revascularized
STEMI found that MVO was more prevalent in younger pa-
tients [29]. These findings are not supported elsewhere in the
literature.
Sex
Females presenting with STEMI, especially when under the
age of 60, have a higher mortality rate than males [98–100].
This has been attributed to atypical symptoms (leading to
delayed presentation and treatment) as well as a possible in-
creased prevalence of microvascular disease [101, 102]. The
impact of cardiac risk factors on mortality is sex-dependent;
e.g., diabetes is more likely to be associated with endothelial
dysfunction in females [100]. Significant associations be-
tween female sex and markers of impaired microvascular re-
perfusion after STEMI have not been consistently reported
[103]. In fact, prospective studies have shown correlation be-
tween male sex and IMH in the acute period following reper-
fusion [6, 30].
STEMI predominately affects men who present at a youn-
ger age with a first MI than is the case for women. This fact
highlights natural sex differences in the epidemiology of is-
chemic heart disease.
Genetic Susceptibility
Genetic variants contribute to an individual’s risk of coronary
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Fig. 2 Predictive factors
associated with MVO
after STEMI
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been identified within certain genes (VEGFA, CDKN2B-
AS1) that correlate with microvascular dysfunction [104,
105]. Research in this area is preliminary and based on micro-
vascular function defined by coronary flow reserve in patient
populations not restricted to myocardial infarction. The appli-
cability of these findings in predicting microvascular reperfu-
sion after MI is limited.
Clinical Presentation
Electrocardiography (ECG)
The 12-lead ECG is the standard-of-care diagnostic assess-
ment in myocardial infarction. The extent of STR has been
used as measure of epicardial reperfusion dating back to the
era of cardiac thrombolysis. Variations of this approach now
form part of contemporary assessment of microvascular dys-
function after revascularized STEMI where complete STR
indicates successful microcirculatory reperfusion and failed
STR (< 30% resolution) or persistent ST-elevation (STE) de-
spite adequate flow appearance is attributed to MVO. ST-
elevation is greater in individuals with MVO before and after
coronary intervention [106]. There are conflicting results re-
garding the utility of STR in detectingMVO [107, 108]. As an
alternative measure, residual STE in either a single lead (max-
imum ST-segment deviation) or combined leads has been as-
sociated with CMR-defined MVO to a greater extent than
STR. Husser et al. demonstrated that sum STE > 3 mm
90 min post-PCI is an independent predictor of MVO (OR
3.1, 95% CI 1.2–8.4; p = 0.02). Other studies report correla-
tion between residual STE and MVO at 48–72 h [106, 108,
109].
QRS duration on presentation has been shown to be inde-
pendently associated with angiographic no-reflow (OR 1.07,
95% CI 1.02–1.12; p = 0.003) [110]. The Selvester QRS score
incorporates multiple criteria in different leads relating to QRS
amplitude and duration [111]. It is a validated tool for
predicting the extent of myocardial damage in STEMI, and
recent studies using CMR demonstrate independent associa-
tion (OR 1.362, 95% CI 1.038–1.951; p = 0.024) and predic-
tive value for MVO (AUC 0.64, 95% CI 0.56–0.72; p =
0.001) [112, 113]. There is no clear association reported be-
tween the presence and extent of pathological Q waves and
MVO development following PCI [108, 114].
Time to Reperfusion
Reducing “door-to-balloon” time improves mortality in
STEMI [115]. Treatment delay in broader terms from symp-
tom onset to reperfusion seems to increase the likelihood of
MVO. For over 40 years, there has been recognized associa-
tion between microvascular dysfunction and myocardial
ischemic time. This was first demonstrated by Kloner in
1974 where the microvascular effects of varying coronary
occlusion times were compared in dogs and defined using
electron microscopy. Only prolonged occlusion (90 min vs.
40 min) resulted in extensive microvascular damage and ede-
ma [116]. A largemeta-analysis examined this more closely in
revascularized STEMI patients. MVO was encountered more
frequently in those with delayed reperfusion in this cohort, in
particularly “symptom to device” time (symptom onset until
beginning of reperfusion procedure) (p = < 0.0001) [9•]. This
is in agreement with previous research in this area [29, 93, 96].
Coronary Lesion Specifics and Clinical Features
The development of MVO is associated with larger infarct
size, anterior infarct location, and reduced initial TIMI grade
[6, 9•]. Individuals with previous coronary intervention are at
increased risk of developing IMH following reperfusion [6].
Previous saphenous vein coronary bypass grafting was report-
ed to increase risk of angiographic no-reflow defined as TIMI
grade 0–1 [117]. Using the same measure in a revascularized
STEMI cohort, target coronary lesion length and thrombus
burden are independent predictors of microvascular dysfunc-
tion [93, 96, 97].
Killip class (extent of heart failure at presentation with
MI) is significantly linked with MVO across a range of
assessment methods [6, 29, 93, 97]. The absence of angi-
na pre-infarction has also been identified as an indepen-
dent predictor of MVO following PCI (OR 8.35, 95% CI
1.27–54.71; p = 0.027) [114, 118], and this observation
has stimulated interest in whether pre-, post- [119], or
remote conditioning might be a novel therapy to prevent
MVO. To date, clinical trial results have not supported
this possibility [120].
Biomarkers
Plasma levels of cardiac troponin are associated with the pres-
ence and extent of MVO following re-perfused STEMI.
Various cut-off values have been proposed that demonstrate
high predictive accuracy, particularly if using peak levels
[121–125]. Peak troponin levels have superior predictive val-
ue compared to ECG scoring parameters (AUC 0.81, 95% CI
0.75–0.87; p = <0.001 vs. AUC 0.64, 95% CI 0.56–0.72; p =
0.001) [112] and considering other biomarkers in addition to
troponin does not seem to increase MVO predictive value
[121].
Elevated circulating N-terminal pro-brain natriuretic pep-
tide (NTpro-BNP) also demonstrates association with MVO
in this population [126]. In a 2013 study, levels remained
significantly elevated in those with MVO complicated by
IMH at each time point over a 3-month period following cor-
onary revascularization [125].
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Other biomarkers that have demonstrated association with
the development of MVO post re-perfused STEMI include
creatinine kinase (CK), high-sensitivity C-reactive protein
(hsCRP), lactate dehydrogenase (LDH), aspartate aminotrans-
ferase (AST), and alanine aminotransferase (ALT)—suggest-
ing a possible link to inflammatory conditions. Mayr et al.
demonstrated significantly elevated CK, hsCRP, and LDH
within the first 4 days following PCI in those later confirmed
to have MVO. These markers all correlated with MVO size
[123]. A CMR follow-up study supported these findings in
addition to linking MVO with significantly elevated levels
of AST and ALT in revascularized MI. In this study, all bio-
chemical parameters shared similar statistical significance in
terms of predicting microvascular dysfunction (AUC 0.68–
0.79) aside from NT-proBNP which was weakly lower
(AUC 0.64, p = <0.05). Although peak values where more
prognostically useful, sensitivity and specificity for MVO
did not exceed 80% [121].
Predictive Scores
An evolving understanding of factors that are associated with
MVO after MI has led to the development of predictive scor-
ing systems. Husser et al. compared clinical parameters, ECG,
biomarker, and angiographic data in the prediction of im-
paired microvascular reperfusion following STEMI. Their
score includes Killip class (double weighting), age < 55, dia-
betes, time to reperfusion, and sum STE. Incidence of MVO
increased with each score increment and is reported as 93%
for scores ≥ 3 (n = 44, p = < 0.001). Predictive value was su-
perior to residual STE or angiographic parameters and similar
to peak troponin levels [29].
Pre-existing scoring systems have been applied to the as-
sessment of microvascular dysfunction after acute MI. The
SYNTAX score uses a combination of coronary characteris-
tics from angiography. Magro et al. demonstrated the utility of
this scoring system as an independent predictor of angio-
graphic no-reflow in 669 patients after revascularized
STEMI (OR 1.29, 95% CI 1.02–1.63; p = <0.001) [127,
128]. The CHA2DS2-VASc score is a widely used predictor
of thromboembolic events in atrial fibrillation. When applied
retrospectively to a STEMI population, it has also been shown
to have predictive value for angiographic no-reflow (OR 1.58,
95% CI 1.33–1.88; p = < 0.001) [129, 130].
Clinical Relevance and Therapeutic Options
for Impaired Microvascular Reperfusion After
MI
Coronary microvascular disease is not benign. Impaired mi-
crovascular reperfusion joins established markers of adverse
cardiac prognosis such as infarct size [131]. In a meta-analysis
investigating microvascular injury in 1025 patients following
STEMI, MVOwas an independent predictor of major adverse
cardiac events HR 3.74, 95% CI 2.21–6.64; p = < 0.001) [64].
This is in concordance with results from a pooled analysis that
included 1688 patients undergoing CMR within 7 days fol-
lowing STEMI. Hazard ratio for all-cause mortality was 1.09
(95% CI 1.01–1.17; p = 0.03) and demonstrated a graded in-
crease dependent on the extent of MVO as a percentage of left
ventricular myocardial mass [9•].
The significance of MVO in patients with acute MI has
spurred research in recent years into the investigation of ad-
junctive therapies that aim to modify MVO and improve out-
comes. Potential interventions include intracoronary drug de-
livery (fibrinolytics and vasodilator therapy), deferred coro-
nary stenting, ischemic conditioning, parenteral beta-block-
ade, and antiplatelets among other pharmacotherapies. To
date, major trial data relating to these methods has largely
failed to demonstrate consistent improvements to either
markers of microvascular reperfusion or MACE.
The METOCARD-CNIC randomized control trial investi-
gated the effect of intravenous metoprolol administered prior
to reperfusion in anterior STEMI with Killip class ≤ 2.
Metoprolol use was associated with a 40% reduction in the
extent of MVO on CMR at 1 week. This remained significant
even when adjusted for infarct size and other confounding
factors. Infarct size and left-ventricular ejection fraction were
improved at 6 months in the metoprolol group but incidence
of MACE at 2 years was comparable [132, 133]. Previous
trials investigating beta-blocker therapy prior to coronary re-
vascularization did not demonstrate benefit in terms ofMACE
or infarct size at 30 days [134].
Studies are underway that are investigating the impact of
novel interventions including pressure-controlled intermittent
coronary sinus occlusion (NCT03625869), localized
intracoronary hypothermia (NCT03447834), selective strate-
gies to defer stenting (NCT01542385) [135], and outcomes
associated with stratified therapy based on non-invasive im-
aging in the management of ischemic heart disease [136].
Conclusion
The mortality and morbidity associated with acute MI remain
significant. Impaired microvascular reperfusion is a common
complication following coronary intervention in this condi-
tion. This is defined as MVO and can be detected at different
time-points across a range of modalities. MVO is under-rec-
ognized, independently associated with adverse cardiac prog-
nosis, and represents an unmet therapeutic need.
A range of factors have emerged that correlate with MVO
after MI. An enhanced understanding of these predictive fac-
tors forms the foundation for a move towards precision med-
icine with individualized risk assessment, investigation, and
21    Page 8 of 13 Curr Cardiol Rep (2021) 23: 21
subsequent stratified therapy with novel treatments. The suc-
cessful modification of this process represents the next thera-
peutic frontier.
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